PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2851006-2	1988	VIP (10(-10) to 10(-6) M) produced a dose-dependent increase in [3H]glycoconjugate release of up to 300% of controls, which was inhibited by VIP antiserum and not inhibited by atropine, propranolol, or phentolamine.	Propranolol	186-197	vasoactive intestinal peptide	Homo sapiens	0-3	
8969945-7	1996	The addition of propranolol, a beta-adrenergic antagonist, to the incubation medium attenuated VIP-induced corticosteroid secretion.	Propranolol	16-27	vasoactive intestinal peptide	Homo sapiens	95-98	
2971708-0	1988	Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction.	Propranolol	49-60	vasoactive intestinal peptide	Homo sapiens	10-39	
2971708-0	1988	Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction.	Propranolol	49-60	vasoactive intestinal peptide	Homo sapiens	41-44	
3297124-0	1987	Effects of indomethacin and (+/-)-propranolol on the cardiovascular and renin responses to vasoactive intestinal polypeptide (VIP) infusion in man.	Propranolol	28-45	vasoactive intestinal peptide	Homo sapiens	91-124	
3297124-4	1987	We recorded the effects of indomethacin and propranolol pretreatment on VIP-related changes in heart rate (HR), blood pressure (BP), forearm vascular resistance (FVR), plasma renin activity (PRA), plasma noradrenaline (PNA) and plasma arginine vasopressin (AVP) concentrations.	Propranolol	44-55	vasoactive intestinal peptide	Homo sapiens	72-75	
3297124-8	1987	Although indomethacin and propranolol reduced the absolute rise in PRA and HR, respectively, during VIP infusion, the percentage changes were no different from control.	Propranolol	26-37	vasoactive intestinal peptide	Homo sapiens	100-103